C-6VCITelomir Pharmaceuticals
epigenetics, metabolism, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-6VCI
C-6VCIC-6VCIepigenetics, metabolism, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a first-in-human, multicenter, open-label Phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral Zn-Telomir monotherapy in adults with advanced or metastatic triple-negative breast cancer. Phase I uses a modified 3+3 dose-escalation design to determine safety, tolerability, maximum tolerated dose, and recommended Phase II dose. Phase II uses a Simon two-stage expansion design at the recommended Phase II dose to evaluate preliminary antitumor activity, including objective response rate per Response Evaluation Criteria in Solid Tumors.
L-Nutra named Innovator Partner for the Longevity Show 2026 Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search DiamiR, AlzLabs team up to ... Xe
225Ac-PSMA-Trillium Shows Promise in Metastatic Prostate Cancer | John Babich posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y … are a major milestone for Telomir Pharmaceuticals, Inc. We’ve submitted our IND application to the FDA for Telomir-1, with the goal of advancing into clinical development for Triple-Negative Breast Cancer. TNBC remains one of the most aggressive cancers, with limited durable treatment options. We believe targeting underlying epigenetic drivers of disease represents a differentiated approach. This milestone reflects years of work from an exceptional team. Pending clearance, th
MinterEllison - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailing l … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
ACCESS Newswire | Markets Insider Business Insider My Markets Watchlist Markets My Markets Watchlist Stocks Indices Commodities Cryptocurrencies Currencies ETFs News Calendar icon An icon in the shape of a calendar. Search Business Strategy Economy Finance Retail Advertising Careers Law Media Real Estate Small Business The Better Work Project Personal Finance Tech Science AI Enterprise Transportation Startups Innovation Markets Stocks Indices Commodities Crypto Currencies ETFs Lifestyle Entertainment Culture Travel Food Health Education Parenting Military & Defense Politics Reviews Home Ki … Integrity Sep. 24, 2025, 09:05 AM Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a... Sep. 24, 2025, 09:00 AM AngelAi Rolls Out Four Powerful Realtor Features at NAHREP - Designed to Empower, Educate, and Accelerate Deal Closures Sep. 24, 2025, 09:00 AM VSee Health Secures Nasdaq Approval for Continued Listing Sep. 24, 2025, 08:30 AM V
Demos: UI Controls and Frameworks --> Demos: UI Controls and Frameworks | DevExpress Chat Now Cart My Downloads Free Trial Log In Products Products MULTI-PLATFORM PACKAGES Universal Subscription Our Best Value – includes over 600 UI Controls, our award-winning reporting platform, DevExpress Dashboard, the eXpressApp Framework, CodeRush for Visual Studio and more. DXperience Subscription Save Hundreds – includes DevExpress UI Controls for WinForms, Blazor, ASP.NET Core (MVC & Razor Pages), ASP.NET Web Forms, MVC 5, WPF, our award-winning reporting platform and CodeRush for Visual Studio. HIGHLI … cumentation Code Examples Demos Training Need help or require more information? Submit your support inquiries via the DevExpress Support Center for assistance. Blogs About Us About Us CONNECT WITH DEVEXPRESS Blogs Events, Meetups and Tradeshows LEARN MORE ABOUT DEVEXPRESS About Us Careers / Job Opportunities News User Comments and Case Studies Our Awards MVP Program Announcing DevExpress Universal v26.1 Developer Express Inc is proud to announce the immediate availability of … ad Download DevExpress WinForms demo applications from GitHub. Outlook-Inspired Application Build apps with the UI elements your customers have come to expect from the world's most popular software suite. Run Demo Dental Clinic Application Create a relatively modern UX – a user experience that can be applied to different industries with minimal changes. Run Demo Stock Market Trader Build WinForms applications that replicate the innovative navigation UI. Run Demo New HTML & … S markup. Run Demo Learn more about HTML & CSS Support Touch-Enabled Hybrid Application Build touch-friendly WinForms applications that meet the evolving needs of your enterprise. Run Demo Fluent Mail Client Application In this demo application we use our Fluent Design Form to replicate Microsoft Mail's UI. Run Demo Help Resources Documentation Online Training Examples Tutorial Videos Getting Started with the Grid Control Getting Started with the Ribbon Control Getting St … UI — Case Study by DataWerkes: Field Services Management Platform (TimeWerkes) Application Security — Documents Are Untrusted Input Application Security — Stronger Hashes and Safer Passwords WPF Demos With over 130 optimized UI controls and libraries, the DevExpress WPF Subscription , can help you create powerful and visually stunning business s
Aberdeen News: Local News, Politics & Sports in Aberdeen, SD Skip to main content Home News Sports Features Opinion Business Obituaries Calendar Crosswords Comics eNewspaper For Subscribers Shopping Contributor Content Discover authentic Peruvian food in Aberdeen Restaurant Costa Brava brings the complex and welcoming flavors of Peru to Aberdeen with dishes like fresh ceviche. Pop's Big Easy brings Cajun flavors and memories to Aberdeen Poll | Which returning area playoff team could win a state football title in 2026? South Dakota Voices CEO speaks at Minneapolis conference regarding ICE polit … e rural and urban divide: St. John's prof writes book local Nonprofit gets $25K grant for family support local Help Terms of Service Subscription Terms & Conditions Privacy Policy Site Map Accessibility Our Ethical Principles Responsible Disclosure Your Privacy Choices © Copyright Gannett 2026
McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday benzinga.com | Benzinga
S-1/A 1 forms-1a.htm As filed with the Securities and Exchange Commission on January 3, 2024 Registration No. 333-275534 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TELOMIR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Florida 2834 87-2606031 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide … asdaq, we will not consummate this offering. No assurance can be given that our application will be approved. Unless otherwise noted, the share and per share information in this prospectus reflects a 1-for-2.05 reverse stock split of our common stock that became effective as of December 11, 2023. We are an “emerging growth company” as defined in the federal securities laws, and, as such, are subject to reduced public company reporting requirements. S … research, publicly available information, and industry publications. We did not fund and are not otherwise affiliated with any of the sources cited in this prospectus. The market research, publicly available information, and industry publications that we use generally state that the information contained therein has been obtained from sources believed to be reliable. The information therein represents the most recently available data from the relevant sources and publications … ng, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements; ● our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; ● our ability to advance product candidates into, and successfully complete, clinical trials; ` … s are ongoing or planned. Upon completion of the toxicology studies, we plan to submit to the FDA an Investigational New Drug application, IND for TELOMIR-1, focused on investigating TELOMIR-1 for the treatment of hemochromatosis. We may consider a second IND for post-chemotherapy recovery. All pre-clinical studies described in this prospectus we
Sault Ste. Marie Evening News: Local News, Politics & Sports in Sault St. Marie, MI Skip to main content Home News Sports Entertainment Lifestyle Opinion Obituaries Crosswords Comics eNewspaper For Subscribers Contributor Content 5 fun things to do this weekend in Northern Michigan It’s all about the arts this weekend in Northern Michigan, with author talks, art shows and more on the schedule. Here’s what we recommend. New invasive species in Michigan damages elm tree leaves in weird patterns University of Michigan raises tuition for in-state students by 3% What age can a child legally stay ho
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $3M Equity Investment to Advance Age-Reversal Pipeline - InvestorWire (IW) About Press Distribution NewsRoom Contact Submit Press Release InvestorWire NewsRoom InvestorNewsBreak InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $3M Equity Investment to Advance Age-Reversal Pipeline Home / InvestorWire NewsRoom / InvestorNewsBreaks / May 21, 2025 InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $3M Equity Investment to Advance Age-Reversal Pipeline Telomir Pharmaceuticals (NASDAQ: TELO) anno … s. Contact our client services team. (862) 930-1404 Distribute a press release. Submit your release to get started. Submit Press Release Set up a Live demonstration. Schedule a date and time that works for you. Schedule a LIVE Demo 1108 Lavaca St Suite 110-IW Austin, TX 78701 twitter facebook linkedin instagram Coin Payments Accepted InvestorWire accepts payments in the following cryptocurrencies United States and Canada distributions have unlimited word count. Additional wor
Telomir Pharmaceuticals Inc. (Nasdaq: TELO) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 114 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> LD Micro Weekend (OS Edition) (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historical Data Share Info Time and Sales Ins
%PDF-1.7 %���� 1 0 obj >/Metadata 1473 0 R/ViewerPreferences 1474 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Pattern >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���Ak�@����9�$��u��$u�J���&+����;k�ةe좋�������>���y9k`p{ Oqd���$2}ȽvVU }=�:�zWS��:�/��Gc����Y ����V�M���w{9 ������U� Eg ��� f �a% B�4�H�Q�l�jU�l- �z֖.�����=�Y�/�Ի)���N�L�:`�HB@�C1�7�O ��RKP,�#J�l���o�ZgF�ړ�u��/�S����? ��P\�Ѩ���D��O� �3 iG�hk�-A���p�o�$���~�oY�2��4�K����:�&�~kbUi��Z{�h&����`�
Telomir Pharmaceuticals, Inc. (Form: 8-K, Received: 10/20/2025 18:48:45) false 0001971532 0001971532 2025-10-17 2025-10-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 17, 2025   TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)   Florida   001-41952   87-2606031 (S … at closing, $2 million upon FDA acceptance of an Investigational New Drug (IND) application for Telomir-1, and $2 million upon initiation of a Phase 1/2 study. Shares corresponding to the $4 million in milestone contributions will be allocated at closing but will not be issued until the respective payments are received. The closing of the Transaction is not contingent upon receipt of the milestone funds.   The LOI provides for a six-month lockup period on the Telomir sha
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings Annual R
Telomir Acquires TELI Pharmaceuticals, Consolidating Global Rights to Telomir-1 | NewsRamp™ posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
QUARTERLY IN DEPTH INVESTMENT ANALYSIS - TELOMIR PHARMACEUTICALS, INC (NASDAQ: TELO) - Spartan Trading Follow us Members Access Register Day Trading Masterclass Swing Trading Invest Ideas Bundles About About Us Trading Resources Contact Us Newsletter Disclaimer, Terms & Conditions Newswire Day Trading Masterclass Swing Trading Invest Ideas Bundles About About Us Trading Resources Contact Us Newsletter Disclaimer, Terms & Conditions Newswire Menu Day Trading Chatroom Learn to Trade Masterclass Swing Trading Long Term Investment Ideas Membership Bundles About Us Trading Resources Newsl … of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results. Generally, the information regarding a compan … aimer Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any busin
%PDF-1.7 4 0 obj > stream x���A��,8�Ux�CJ$%-��p����A����E ��t�Y�u_���%YE ䷥����-g�G���l�������I��������mZ���K�o��N���e)om:�GF�h����N]� ǟ������_�{(��A���oe>���m{���ܾ}��[�� O7�͌Mo�Xlz[fF�mG�����_��4N�m�cG��㧷���;xT�4��`���/Q��b/Z�z��S��p���oe��-����-;���mAd\9�(/@��b}\ �e Zt�#x�!(wwԉc�}���v��>�������+ ��5�����S�E��� �%+ ��!���c���o���C���+�ϙy��o̕�l /�0٧�j�t �t8汾�+#[� ��$��k�d ����X����,�Y����;�g�� �/ Ӄ���#��}9��z�O�I�*�H��4)�81 *'�wza���E��{I��^��)*v���}4#Hn�`�I+�>��|]�p�!*�+�{r�Yw�L���w#?cn[l�>��g26 >��a��'m�7's�L�F����ۺ���$q ��I�=�Ʉ�d�u\V�$N `2�����0
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Telomir Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 28 Apr 2026 Telomir Pharmaceuticals, Inc. Startups | Public Company | 2022 | Maryland, United States | < 10 | NASDAQ: TELO | telomirpharma.com Startups | Public Company | 2022 | Maryland, United States | < 10 | NASDAQ: TELO | telomirpharma.com Last update 28 Apr 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Infectious Diseases Endocrinology and Metabol … Triple Negative Breast Cancer [+8] Inactive Indication - Drug Highest Phase IND Application First Approval Ctry. / Loc. - First Approval Date - Telomir-Ag1 Target - Mechanism - Active Org. Telomir Pharmaceuticals, Inc. Originator Org. Telomir Pharmaceuticals, Inc. Active Indication Bacterial Infections Inactive Indication - Drug Highest Phase Preclinical First Approval Ctry. / Loc. - First Approval Date - Telomir-Ag2 Target - Mechanism - Active Org. Telomir Pharmaceuticals, I … velopment milestones, including acceptance of an Investigational New Drug (IND) application and initiation of a Phase 1/2 clinical trial, and are subject to participation by such shareholders, aligning potential capital support with clinical advancement. Clinical Development The closing follows Telomir's recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-Zn for the treatment of advanced and metastatic … terstock.com. Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its lead candidate targeting advanced and metastatic triple-negative breast cancer (TNBC). The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial of Telomir-1 … ed disease, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1 (Telomir-Zn), for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC). The IND submission includes data from completed IND-enabling pharmacology, toxicolog
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings Annual Reports Quarterly … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by
Moomoo AI: RE: Telomir Pharmaceuticals | PRER14A: Preliminary revised proxy soliciting materials What’t up with this TELO merger? Who is TELI? And what’s being proposed and why? Explain to me like I’m 5, please.🙏 $Telomir Pharmaceuticals (TELO.US)$
Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares Less than 1 min read TELO Telomir Pharmaceuticals completed the all-stock acquisition of TELI Pharmaceuticals, issuing 34,389,710 restricted shares based on independent valuations, and consolidating worldwide rights
Telomir Pharmaceuticals Mourns the Passing of Chairman and --> Accessibility: Skip TopNav Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman August 12, 2024 08:30 ET | Source: TELOMIR PHARMACEUTICALS, INC. TELOMIR PHARMACEUTICALS, INC. Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by
Cash Flow - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Investor Relations Cash Flow Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings Annual Reports Quarterly Results Section 16 Filings GOVERNANCE Overview Board of Directors Bo
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic D … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press r
Telomir Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026 Download About Us Support العربية Invest Products Pricing Academy Free Stocks Hot Trading Sahm ID My Account Log Out Sign up / Log in Open Account Open Account Home News Detail Telomir Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026 Benzinga News 09/06 00:03 العربية Like Facebook Twitter Email Link Share Facebook Twitter Email Link Cancel Telomir Pharmaceuticals, Inc. Telomir Pharmaceu
Telomir Pharmaceuticals Announces Closing of Initial Public Offering - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings Annual Reports Quarterly Results Section 16 Fili
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All … ts that discipline.” From an operational standpoint, our first goal is to submit our IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way. We believe pursuing a rare disease indication gives us a strategic entry point to demonstrate clinical impact and build broader value. Advancing a Growing Pipeline with Breakthrough Potential Telomir is advancing two highly innovative drug candidates: Telomir-1, a first-in-class age
Proactive - Telomir Pharmaceuticals Inc. Co-Founder Frank... Facebook Log In Proactive's Post Proactive May 7, 2024 · Shared with Public Telomir Pharmaceuticals Inc. Co-Founder Frank O’Donnell joined Steve Darling from Proactive to share what the company believe is groundbreaking potential of their new drug designed to extend telomeres, which could reverse aging and age-related diseases. During a recent interview, O'Donnell elaborated on the drug’s potential, supported by extensive research in mice and successful trials in larger animals like a German shepherd. Watch at #Proactive #P
TELO SEC Filings - Telomir Pharms 10-K, 10-Q, 8-K Forms --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas Defense … 08:00 PM Filing Telomir (TELO) director swaps 25K options for new lower-priced grant Rhea-AI Summary Telomir Pharmaceuticals director Edward Clouston MacPherson restructured his stock options with no net change in option count. He agreed to cancel an existing option for 25,000 shares of common stock with a $5.02 exercise price and an expiration on August 27, 2034. In exchange, he received a new option for 25,000 shares at a lower exercise price of $1.30, expiring on May 21, … expiration, as a disposition back to the issuer. In exchange, he received a new grant of 25,000 incentive stock options for common stock with a lower exercise price of $1.30 per share and a May 21, 2036 expiration. Following these transactions, he holds 25,000 stock options directly, and no common shares were bought or sold in the market. Rhea-AI Impact Rhea-AI Sentiment End-of-Day -- % Tags insider - 05/20/2026 08:00 AM Filing Wilson’s disease study backs Telomir-Zn for Telo … the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir‑Zn , the company’s lead product candidate, to treat advanced or metastatic triple‑negative breast cancer. The company plans a first‑in‑human Phase 1/2 trial starting in the first half of 2026, enrolling about 76 patients. Phase 1 will focus on safety, tolerability, dose‑limiting toxicities, pharmacokinetics, pharmacodynamics, and early antitumor activity to determine the re
Telomir to Merge With TELI in 50/50 Stock Deal | TELO SEC Filing - Form PRER14A --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto S … oore. Execution now hinges on stockholder approval of the merger share‑issuance proposal and satisfaction of conditions such as TELI holding at least $1M in cash or marketable securities at closing, plus specified funding commitments at future Telomir‑1 milestones. Subsequent company filings and clinical/regulatory milestones, such as submission and potential FDA acceptance of an IND for Telomir‑1, will determine how the capital structure and development pathway evolve. See m … prior to the Merger, pursuant to Nasdaq Listing Rule 5635(a) (the “Merger Proposal” or “Proposal No. 1”); 2. elect four directors to the board of directors of the Company (the “Board”) to serve until the next annual meeting of stockholders or until their successors have been duly elected or appointed and qualified (“Director Appointment Proposal” or “Proposal No. 2); … rm for the fiscal year ending December 31, 2025 (the “Auditor Appointment Proposal” or “Proposal No. 3”); 4. approve certain amendments to the Company’s 2023 Omnibus Incentive Plan (the “Plan”) (“Plan Amendment Proposal” or “Proposal No. 4”); 5. approve an amendment to the Company’s Bylaws to reduce the quorum requirement for a shareholder meeting; ( … the quorum requirement for a shareholder meeting; (the “Bylaws Amendment Proposal” or “Proposal No. 5”); 6. approve certain grants of options to non-executive members of the Board (the “Director Option Grants Proposal” or “Proposal 6”); and 7. approve a pos
%PDF-1.7 %���� 1 0 obj >/Metadata 1096 0 R/ViewerPreferences 1097 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��W�N�@}����]$ov��B�"�r)Iۇ�� BKi+U��ά�����5�zΜ3;3�m��^��Nn���6�Q�)���U`�+�b7ge�y�Mʢ�;pl��,���/+ʸ������CY�>~���e[턞�v����M��~dpOv�D`r$>G�d���5�&c��nY��)�l�}^�~H�83\�Š �2� /X��,�D[C�D�0��9LAKFI��K�_M���p_��]Y�wH�w���{��{;Lml���m�M�SG��Ǖ���ig��K��159�� � #n� ��B��Û3D 00�,��o xo�}4�{ҽ��ɘ�I�q n�$�f� �Rh�
Telomir Pharmaceuticals, Inc. (Form: S-1/A, Received: 12/14/2023 17:10:29) As filed with the Securities and Exchange Commission on December 14, 2023 Registration No. 333-275534 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TELOMIR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Florida 2834 87-2606031 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial … asdaq, we will not consummate this offering. No assurance can be given that our application will be approved. Unless otherwise noted, the share and per share information in this prospectus reflects a 1-for-2.05 reverse stock split of our common stock that became effective as of December 11, 2023. We are an “emerging growth company” as defined in the federal securities laws, and, as such, are subject to reduced public company reporting requirements. S … research, publicly available information, and industry publications. We did not fund and are not otherwise affiliated with any of the sources cited in this prospectus. The market research, publicly available information, and industry publications that we use generally state that the information contained therein has been obtained from sources believed to be reliable. The information therein represents the most recently available data from the relevant sources and publications … ng, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements; ● our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; ● our ability to advance product candidates into, and successfully complete, clinical trials; ` … s are ongoing or planned. Upon completion of the toxicology studies, we plan to submit to the FDA an Investigational New Drug application, IND for TELOMIR-1, focused on investigating TELOMIR-1 for the treatment of hemochromatosis. We may consider a second IND for post-chemotherapy recovery. All pre-clinical studies described in this prospectus we
Telomir Pharmaceuticals, Inc. (Form: 8-K, Received: 05/20/2026 08:00:59) false 0001971532 0001971532 2026-05-20 2026-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): May 20, 2026   TELOMIR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)   Florida 001-41952   87-2606031 (State or Oth
TELOMIR-1 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 12 May 2026 TELOMIR-1 Last update 12 May 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms Telomir-Zn Target ASC x IL-17 x STAT1 Action agonists, inhibitors Mechanism ASC agonists(Apoptosis-associated speck-like protein containing a CARD agonists), IL-17 inhibitors(Interleukin-17 inhibitors), STAT1 agonists(Signal transducer and activator of … velopment milestones, including acceptance of an Investigational New Drug (IND) application and initiation of a Phase 1/2 clinical trial, and are subject to participation by such shareholders, aligning potential capital support with clinical advancement. The closing follows Telomir's recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-Zn for the treatment of advanced and metastatic triple-negative breas … g Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC). This IND clearance enables the Company to advance Telomir-Zn into clinical evaluation, representing an important step toward addressing a significant unmet need in patients with advanced or metastatic triple-negative breast cancer, where treatment options … terstock.com. Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its lead candidate targeting advanced and metastatic triple-negative breast cancer (TNBC). The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial of Telomir-1
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings Annual Reports Quarte … this trial could be used to enable our submission of an Investigation New Drug Application to the FDA to study the potential effect of Telomir-1 on osteoarthritis in humans.” “Based on our initial research, we believe that Telomir-1 can offer an effective disease-modifying therapy that enhances the quality of life and mobility for canines with osteoarthritis,” commented Dr. Michael Roizen, Special Advisor on Age Reversal to Telomir Pharmaceuticals.   … rthritis. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of the Company’s management related thereto contains “forward-looking statements,” which are statements other than historical facts made pursuant to the safe
RESEARCH | Overview Overview THE SCIENCE RESEARCH RESEARCH PIPELINE ABOUT US MANAGEMENT BOARD OF DIRECTORS ADVISORS NEWS & EVENTS INVESTORS CONTACT US Select Page RESEARCH Key ongoing initiatives THERAPEUTIC FOCUS AREAS Type 2 Diabetes Studies Building on zebrafish success, Telomir is testing a rat diabetic model to confirm Telomir-1’s efficacy in reversing metabolic parameters, including reduced insulin resistance (HOMA-IR). PROGERIA RESEARCH Following promising C. elegans results, Telomir-1 restored lifespan and normalized aging in wrn-1 mutant nematodes (a model for Werner Syndrome), w
PIPELINE | Overview Overview THE SCIENCE RESEARCH RESEARCH PIPELINE ABOUT US MANAGEMENT BOARD OF DIRECTORS ADVISORS NEWS & EVENTS INVESTORS CONTACT US Select Page PIPELINE ANTICIPATED TIMELINE FOR TELOMIR-1 2026 Q2 Toxicology : Completion of formal toxicology Regulatory : Prepare IB (Investigational New Drug Application). IND submission Clinical : Formal toxicology 2026 Q3 Regulatory : Initiation of Phase I/II studies 2026 Q4 Regulatory : Ongoing Phase I/II studies 2026 Q4 Regulatory : Ongoing Phase I/II studies market opportunity Summary of US Epidemiology The eligible patient pool analy
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings
Telomir-1 Shows No Treatment-Related Toxicities in IND-Enabling Studies | Telomir Pharmaceuticals, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Cont … t BLT is pleased to announce its 2026 Travel Grants. This year, #BLT will again award five travel grants to support young scientists attending an international toxicology conference. Eligible meetings are: — SoHT Society of Hair Testing – New York (14–15 May) — SFTA – Aix-en-Provence (18–21 May) — The European Association of Poison Centres and Clinical Toxicologists (EAPCCT) – Vilnius (26–29 May) — The International Association of Forensic Toxicologists – TIAFT / SOFT – Chica … s of age. All criteria and submission instructions can be found on our website. Deadline: 31 May 2026. 11 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Rob Moore 1mo Report this post A week or so ago I shared the recent ACMD update on novel synthetic opioids and was slightly surprised by how much engagement it received. This week’s Tox Lab episode explores some of those developments further — including emerging opioid analogues such as cyclorph
I would like to thank my sponsor Telomir Pharmaceuticals, Inc. and my employer Frontage Laboratories, Inc for the wonderful opportunity to present the work on TELOMIR-1 at the Unlocl Healthy… | Danielle Piazza Baker, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filin
--> Telomir Pharmaceuticals Signs Key Media Partnership - TELO | BioP --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
%PDF-1.7 4 0 obj > stream x���Mv�8,8�*���$���5�9��@w���-[DfddJ�,���r�\qI�A "#����C~���������������y�'� ���{)��n���ul��Ne����2 �'#~0��_��Ԗ�8� ��{�_���=���A����q~���_��vŷ�|� �3��[�o72�n3c�k-6��3#mۑ���1��2�N��\�?v�� S?~ݑ���l��b�l��'l�Dym�^���~yّ�����P�u���9�8�.��z���"2�� O� �A��/�ڟ�}T���������ږ3�����a�HRw� ^�#��1A��N��V�`�������A'����ϯ��g� #���G7��N�ֱ��|ѣ_7�.(mc��nH�*�ֲ���v�� �1 �����E^�|���H���k��B��Y�c��k�e��5H~A���Y��[?��cul����d�a�����>K�|A�� D�%#���y�y� � P���=R�@��h0��O*}M2G�;�d����0,�ݾj�uq��uL3�4��F��=�7&�l��Q����֖e����M�%�ũ�_W�_��K�w��^� �֯�� �.Au
false 0001971532 DEFM14A 0001971532 2024-01-01 2024-12-31 0001971532 2023-10-02 2024-01-01 2024-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934     Filed by the Registrant ☒   Filed by a Party other than the Registrant ☐   Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (a … prior to the Merger, pursuant to Nasdaq Listing Rule 5635(a) (the “Merger Proposal” or “Proposal No. 1”);         2. elect four directors to the board of directors of the Company (the “Board”) to serve until the next annual meeting of stockholders or until their successors have been duly elected or appointed and qualified (“Director Appointment Proposal” or “Proposal No. 2);         … rm for the fiscal year ending December 31, 2025 (the “Auditor Appointment Proposal” or “Proposal No. 3”);         4. approve certain amendments to the Company’s 2023 Omnibus Incentive Plan (the “Plan”) (“Plan Amendment Proposal” or “Proposal No. 4”);         5. approve an amendment to the Company’s Bylaws to reduce the quorum requirement for a shareholder meeting (t … e the quorum requirement for a shareholder meeting (the “Bylaws Amendment Proposal” or “Proposal No. 5”);     6. approve certain grants of options to non-executive members of the Board (the “Director Option Grants Proposal” or “Proposal 6”); and         7. approve a postponement or adjournment of the TELO Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes i … ry, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1, Proposal No. 2, Proposal No. 3, Proposal No. 4, Proposal No. 5, or Proposal No. 6, “the “Adjournment Proposal” or “Proposal No. 7”.   Please refer to the attached proxy statement for further information with respect t
EX-31.1 2 ex31-1.htm Exhibit 31.1 SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER I, Erez Aminov, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Telomir Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the fin
$TELO Telomir... - Telomir Pharmaceuticals Inc. Facebook Log In Telomir Pharmaceuticals Inc.'s Post Telomir Pharmaceuticals Inc. December 1, 2025 · Shared with Public $TELO Telomir Pharmaceuticals, Inc. Reports New Data on Telomir-1 in Prostate Cancer Cells New findings show Telomir-1 significantly reduces PSA levels — a key FDA-recognized biomarker of prostate cancer activity — in human prostate cancer cells. Today, most available treatments can extend life but often come with serious trade-offs: fatigue, metabolic effects, cardiovascular strain, and sexual side effects that impact quali
Telomir Pharmaceuticals Submits IND Application for Telomir-1 in TNBC | Telomir Pharmaceuticals, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Contin … People Learning Jobs Games Join now Sign in Telomir Pharmaceuticals Submits IND Application for Telomir-1 in TNBC Telomir Pharmaceuticals, Inc. 2,077 followers 2mo Edited Report this post $TELO A Major Milestone for Telomir Pharmaceuticals, Inc. We are pleased to announce the submission of our IND application to the FDA for Telomir-1(Telomir-Zn), our lead candidate targeting advanced and metastatic Triple-Negative Breast Cancer. This marks a critical transition from preclinic
Telomir Pharmaceuticals presents at AACR 2026 on TNBC treatment | Telomir Pharmaceuticals, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
Home Skip to main content Home News Entertainment Obituaries Travel Contributor Content Collier County’s new Congressional district means new faces local Advocates gather at 'Alligator Alcatraz' for final vigil as detainees are moved government 3 To Know: Resilient coral reefs; one dead in crash; other headlines local SWFLA To Do List: Events in Bonita, Estero, Naples and Marco Island life Now You Know: Shake Shack coming to South Naples; Wine Fest updates local Florida Lotto for Saturday, June 24, nears $6 million ahead of July 4 news Powerball for Saturday, June 27, week after Florida ticket
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart H
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart H … a night. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of the Company’s management related thereto contains “forward-looking statements,” which are statements other than historical facts made pursuant to the safe
TELO Insider Buying — Recent SEC Form 4 Activity (2026) | InsiderAct | InsiderAct Insider Act Home Signals Insiders Transactions Watchlist Learn Subscribe Home / Stocks / TELO TELO Insider Buying — Recent SEC Form 4 Activity Track insider buying activity for Telomir Pharmaceuticals, Inc. ( $ TELO ). See every SEC Form 4 purchase by CEOs, CFOs, directors, and 10% owners over the last 90 days — sourced directly from EDGAR. No insider purchases recorded for Telomir Pharmaceuticals, Inc. (TELO) in the past 90 days. Purchases (90d) 0 Total value — Unique insiders 0 See full $ TELO insider activity
TELO-Telomir Pharmaceuticals, Inc.-ETF其他成份股-美股-MoneyDJ理財網 加入會員 --> 美股首頁 首頁 我的觀察名單 個股資料 基本資料 行情報價 基本分析 股價評價分析 股價淨值比 本益比 市價報酬率 相關公司 同類股 細產業 指數成分股 ETF成分股 相關新聞 排 行 報酬排行 漲幅排行 跌幅排行 距52週高點%排行 距52週低點%排行 連續上漲天數排行 連續下跌天數排行 超買排行 超賣排行 基本資料排行 成交量排行 成交值排行 流通股數排行 標準差排行 本益比排行 股價淨值比排行 ROA排行 ROE排行 ROIC排行 EPS排行 毛利率排行 員工人數排行 股東人數排行 Beta排行 社群排行 點擊排行 查詢次數排行 新聞筆數排行 列 表 美國市場18大指數列表 重要指數成份股清單 美國行業成份股清單 美國標普500十一大類股成份清單 工 具 ADR套利 選股工具 公司資料選股 基本面選股 技術面選股 投資策略 定期定額回測 定期定值回測 定期定股回測 隨機投資回測 金字塔投資策略回測 行事曆 各類股績效表現 特別股 特別股搜尋 特別股ETF 特別股個股 基本資料 行情報價 配息紀錄 報酬走勢 相關商品 發行公司 基本資料 歷史股價 財務比率 財務報
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SE
Telomir Pharmaceuticals Inc. (Nasdaq: TELO) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 114 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> LD Micro Weekend (OS Edition) (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historical Data Share Info Time and Sales Ins
Presentation - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Presentation Contact Us Follow Follow Follow Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us ADA COMPLIANCE TERMS & CONDITIONS PRIVACY POLICY © 2024 Telomir Pharmaceuticals. All Rights Reserved. This site is not intended to provide medical advice or to suggest that any product mentioned is safe or efficacious for any disease or condition. Corporate Governance
Presentations - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Investor Relations Presentations Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings Annual Reports Quarterly Results Section 16 Filings GOVERNANCE Overview Board of Dire
Telomir Pharmaceuticals Inc. (Nasdaq: TELO) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 114 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> LD Micro Weekend (OS Edition) (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historical Data Share Info Time and Sales Ins
#bio2026 #bioconvention #biotech #partnering #oncology #cipn #tnbc #drugdevelopment | Telomir Pharmaceuticals, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data … rtunities, and potential M&A transactions. Telomir is actively preparing to submit an Investigational New Drug (IND) application by the end of this year for its lead candidate, Telomir-1 -a novel small molecule designed to elongate telomeres, regenerate cells , and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA , with the goal of initiating first-in-human dosing in the first half of 2026. As part of its expandin
Mira Pharmaceuticals, Inc. / Telomir Pharmaceuticals, Inc. - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Release … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Epigenetic Prostate Cancer Therapy Shows Promising Early Results | Inside Precision Medicine clinicalomicsprowebdirectory Facebook Linkedin Twitter News Topics Informatics Molecular Dx Patient Care Oncology Precision Medicine Translational Research Magazine Browse Issues Subscribe Subscribe Get Inside Precision Medicine Magazine Get Inside Precision Medicine eNewsletters Multimedia Webinars Summits Podcasts Videos Inside Precision Medicine Live Learning Labs eBooks Search Facebook Linkedin Twitter Sign in Welcome! Log into your account your username your password Forgot your password? Get help
EX-10.4 2 ex10-4.htm Exhibit 10.4 AMENDED & RESTATED EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of August 11, 2023 and is retroactive to November 29, 2022 (the “Effective Date”), when the Exclusive License Agreement was first entered by and between MIRALOGX LLC, a Florida limited liability company located at 900 West Platt St., Suite 200, Tampa, FL 33606 (“Licensor”) and TELOMIR PHARMACEUTICALS, INC., a Florida corporation having its principal place of business at 855 North Wolf … s, files, and books of account will be subject to audit. ARTICLE 3—GRANT OF LICENSE AND RIGHT TO SUBLICENSE 3.1 Grant of Exclusive License. In consideration of and subject to payment of royalties under Article 2 hereof, Licensor hereby grants to Licensee an exclusive license under the Patent Rights to make, have made, use, and sell Licensed Products in the Licensed Territory and solely in the Field of Use during the Term of Agreement. 3.2 Grant of N … The licenses granted in Sections 3.1 and 3.2 includes the right of Licensee to grant corresponding Sublicenses to third parties during the Term of Agreement. ARTICLE 4—PATENT MARKING 4.1 Patent Marking. Licensee agrees that all Licensed Products sold by Licensee, Affiliates, or Sublicensees will be legibly marked with the number of any applicable patent(s) licensed hereunder as part of the Patent Rights in accordance with Title 35, U.S. Code, or if such m … its cost; thereafter, Licensor shall enter into an assignment of that patent or application and all rights thereunder to Licensee. 6.4 Licensor Patent Applications. If Licensor desires to abandon the prosecution of any patent application falling within the Patent Rights, it shall give Licensee written notice of such intention not less than forty-five (45) days prior to the applicable fee payment or abandonment deadline. The notice shall identify the application in ques … at its cost; thereafter, Licensor shall enter into an assignment of that patent application and all rights thereunder to Licensee. Licensee shall only pursue claims to the Licensed Product in the Field of Use in any applications assigned under Section 6.4. ARTICLE 7—MISCELLANEOUS 7.1 Relationship of Parties . Nothing in this A
Telomir Pharmaceuticals Inc. (NASDAQ: TELO) - IBN (InvestorBrandNetwork) About Clients Content Events Newsletters Solutions Contact Clients Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Home > Clients > Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Investment Considerations Telomir Pharmaceuticals is pioneering the development of Telomir-1, a novel small molecule with the potential to address the root causes of aging and age-related conditions by lengthening telomeres, positioning the company at the forefront of the emerging longevity market. The c … the Nobel Assembly at the Karolinska Institute in 2009, which awarded the Nobel Prize in Physiology or Medicine for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. By leveraging this foundational knowledge, Telomir Pharmaceuticals seeks to develop a novel therapeutic approach that could revolutionize the field of longevity and age-related health. Telomir Pharmaceuticals’ broader mission is to enhance overall quality of life by slow … rman Shepherd, who has been receiving daily doses of Telomir-1. This real-world application aims to provide valuable data on the effectiveness and safety of Telomir-1 in treating age-related conditions, which will inform the company’s future research and regulatory strategies. As Telomir-1 progresses through pre-clinical trials, it represents a significant step forward in the company’s mission to develop innovative therapies that address the challenges of aging. M … sure to an audience of millions, including journalists, investors, day traders, fund managers and a multitude of other interested individuals. Now your press releases, earnings statements, branded articles, shareholder updates, corporate achievements can reach a vast and diverse nationwide audience. More About InvestorWire Account Setup Campaign Strategy Content Creation Crisis Communications Editorial Calendars Focus Groups Full Management Messaging & Branding Social Me
Overview | Age Reversal Overview THE SCIENCE RESEARCH RESEARCH PIPELINE ABOUT US MANAGEMENT BOARD OF DIRECTORS ADVISORS NEWS & EVENTS INVESTORS CONTACT US Select Page DEVELOPING POTENTIAL FIRST-IN-CLASS EPIGENETIC ONCOLOGY PLATFORM Targeting Metal-Dependent Epigenetic Dysregulation Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer and age-related disease. Its lead investigational candidate, Telomir-Zn, is designed to restore epigenetic regulation associate
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Angel indiv page | Overview Overview THE SCIENCE RESEARCH RESEARCH PIPELINE ABOUT US MANAGEMENT BOARD OF DIRECTORS ADVISORS NEWS & EVENTS INVESTORS CONTACT US Select Page Itzchak Angel , Ph.D. Chief Scientific Advisor Itzchak Angel is an accomplished executive in the pharmaceutical industry, with over 40 years’ experience guiding medical, pharmaceutical, drug and business development in both large and emerging companies. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.) where he assists pharmaceutical and biotechnology companies, in
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Press Releases Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press r
Board of Directors - Telomir Pharmaceuticals, Inc. (TELO) Overview The Science About Us Management Board of Directors Advisors News & Events Investors Contact Us Select Page Investor Relations Board of Directors Investor relations Overview News & Events Press Releases In the News IR Calendar Presentation Email Alerts Company Info Company Profile Management Contacts FAQ Financial Info Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote and Chart Historic Data SEC Filings All SEC Filings Annual Reports Quarterly Results Section 16 Filings GOVERNANCE Overview Boa … and leading the company to the submission of an Investigational New Drug (IND) application. His strategic guidance played a central role in MIRA’s successful initial public offering (IPO), establishing it as a leader in its field. With a wealth of experience in biotechnology consulting, investment, and leadership, Mr. Aminov also founded Locate Venture Corp, where he supported early-stage biotech enterprises. He has been a driving force behind the IPOs of both MIRA Pharmaceu … M.D. from Loyola University Stritch School of Medicine, completed his radiology residency at Loyola University Medical Center, and his musculoskeletal radiology fellowship at the University of Arizona Health Sciences Center – Tucson. Dr. Del Giudice is licensed to practice medicine in Florida and Ohio. We believe that Dr. Del Giudice is qualified to serve as one of our directors based on his extensive experience as a radiologist. Ned MacPherson Director Ned MacPherson, age 36
Aminov indiv page | Overview Overview THE SCIENCE RESEARCH RESEARCH PIPELINE ABOUT US MANAGEMENT BOARD OF DIRECTORS ADVISORS NEWS & EVENTS INVESTORS CONTACT US Select Page Erez Aminov Chairman and Chief Executive Officer Erez Aminov is the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a biotechnology company pioneering age-reversal science. Under his leadership, Telomir has advanced innovative therapies targeting age-related conditions, including Type 2 Diabetes, aging, and Progeria—a rare and fatal genetic disorder characterized by accelerated agin … and leading the company to the submission of an Investigational New Drug (IND) application. His strategic guidance played a central role in MIRA’s successful initial public offering (IPO), establishing it as a leader in its field. With a wealth of experience in biotechnology consulting, investment, and leadership, Mr. Aminov also founded Locate Venture Corp, where he supported early-stage biotech enterprises. He has been a driving force behind the IPOs of both MIRA Pharmaceu
Key Sponsors - snnla.org About Us Mission + Values Board of Directors Leadership Team Diversity and Inclusion Our Story Letter from our Founder The Need SNN Stories Journey to the Autism Center Media Media Requests Press Releases Photo Gallery Videos Support Donate Volunteer Celebrity Supporters Community Partners Key Sponsors Sponsorship Opportunities Programs Autism Health + Wellness In-home + Center-based ABA, Speech + OT Concierge Assessment + Therapeutic Program JPAC Fundays at CADD Advocacy + Social Justice Tools for Transformation Parent Advocacy Mentor Program (PAM) Ask the Experts Hel … Pipeline to Treatment for Foster Youth Workforce Development C.O.R.E Workforce Grant Flavourista Culinary Arts/Hospitality Training Program Youth Employment Leadership and Empowerment + Accessibility (YELEP+A) Special Flavours Education + Training PAM College Advocacy + Readiness Program Joe Patton Academy Camp (JPAC) Joe Patton Academy – Kickin’ It Together Soccer Program Community Engagement + Support THINK Autism UCLA Autism Genetics and Human diversity Project An SNN/UCL
Jazz Pharmaceuticals Acquires Chimerix in Rare Oncology Push | Xiaojun Yang posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
false FY 0001971532 0001971532 2025-01-01 2025-12-31 0001971532 2025-06-30 0001971532 2026-03-12 0001971532 2025-12-31 0001971532 2024-12-31 0001971532 2024-01-01 2024-12-31 0001971532 us-gaap:CommonStockMember 2023-12-31 0001971532 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001971532 us-gaap:RetainedEarningsMember 2023-12-31 0001971532 2023-12-31 0001971532 us-gaap:CommonStockMember 2024-12-31 0001971532 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001971532 us-gaap:RetainedEarningsMember 2024-12-31 0001971532 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001971532 us-gaap:Addi … eding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth co … license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.   Risks Related to Our Operations and Financial Condition   We are an early development-stage company with no revenues and our financial condition raises substantial doubt as to our ability to continue as a going concern.   Because we have a limited operating his … preclinical studies and may not be predictive of clinical outcomes. We plan to submit an IND application in 2026 and, if the IND becomes effective and other conditions are satisfied, to commence a Phase 1/2 clinical trial thereafter. The timing of these activities is subject to change and may be delayed due to regulatory, technical, manufacturing, financing, or other factors   TELI Pharmaceuticals, Inc., a private related party company incorporated under the laws of Del … tivities in support of a potential Investigational New Drug (“IND”) application. We are targeting IND submission in 2026 and, subject to regulatory review, completion of required preclinical and manufacturing activities, and availability of resources, plans to initiate a Phase 1/2 clinical trial thereafter. The timing of these activit
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer April 30, 2026 | 6 min read Twitter LinkedIn Facebook Email Print Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCE … g Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC). This IND clearance enables the Company to advance Telomir-Zn into clinical evaluation, representing an important step toward addressing a significant unmet need in patients with advanced or metastatic triple-negative breast cancer, where treatment options … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals B … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 December 3, 2024 | 8 min read Twitter LinkedIn Facebook Email Print Building on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 app … other age-related inflammatory conditions. Cancer Models: Exploring Telomir-1's application in combating age-related oncological conditions. Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, elaborated: "These findings confirm Telomir-1's potential to not only manage diabetes effectively but to fundamentally change how we view chronic disease treatment. By targeting the root causes of insulin resistance, Telomir-1 offers a potential paradigm shift in diabetes management … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging February 5, 2026 | 7 min read Twitter LinkedIn Facebook Email Print Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfun … d data package to support regulatory submission. The Company currently plans to submit an Investigational New Drug (IND) application in the first quarter of 2026. In parallel, Telomir continues to advance a portfolio of ongoing and completed preclinical research programs, including studies in triple-negative breast cancer (TNBC) models and longevity-focused models , evaluating the biological relevance of Telomir-Zn's intracellular metal-modulating and epigenetically associate … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search New … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging) January 8, 2025 | 7 min read Twitter LinkedIn Facebook Email Print MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth October 21, 2025 | 7 min read Twitter LinkedIn Facebook Email Print Unifying global IP rights and enabling up to $5 million in potential shareholder contribu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price December 12, 2024 | 6 min read Twitter LinkedIn Facebook Email Print Transaction follows a $5 million non-dilutive credit line from the same trusted partner, … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications September 4, 2024 | 8 min read Twitter LinkedIn Facebook Email Print MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telom … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells March 19, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Telomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemothera … The company is prioritizing the fastest pathway to clinical trials and aims to submit its Investigational New Drug (IND) application by year-end. "We are working aggressively to submit our IND by year-end," said Aminov . " As we continue optimizing our drug manufacturing processes and advancing pre-IND animal safety studies, our team is laser-focused on bringing Telomir-1 one step closer to clinical trials. Every milestone we achieve reinforces our belief that Telomir-1 has … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND May 21, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's … reflects that discipline." From an operational standpoint, our first goal is to submit our IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way. We believe pursuing a rare disease indication gives us a strategic entry point to demonstrate clinical impact and build broader value. Advancing a Growing Pipeline with Breakthrough Potential Telomir is advancing two highly innovative drug candidates: Telomir-1, a first-in-class age … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia May 7, 2025 | 6 min read Twitter LinkedIn Facebook Email Print MIAMI, FLORIDA / ACCESS Newswire / May 7, 2025 / Telomir Pharmaceuti … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman August 12, 2024 | 4 min read Twitter LinkedIn Facebook Email Print Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMP … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufac … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 November 21, 2024 | 7 min read Twitter LinkedIn Facebook Email Print MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telo … of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Canton Repository: Local News, Politics & Sports in Canton, OH Skip to main content Home News Communities Sports Entertainment Lifestyle Opinion Business Obituaries Crosswords Comics eNewspaper For Subscribers Shopping Contributor Content Grocery Shopping Data center 101. Learn the basics of data centers, their impact Data centers have sprung up like dandelions across Ohio. Here's a Q&A explaining the basics about them. Magnolia unveils statue of Browns star Vince Costello See who made 2026 Repository All-Stark County Softball Teams HS Baseball | See who made the 2026 Repository All-Stark Coun
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) April 24, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Transaction establishes global ownership rights of lead program and includes initial capital funding with additional opt … velopment milestones, including acceptance of an Investigational New Drug (IND) application and initiation of a Phase 1/2 clinical trial, and are subject to participation by such shareholders, aligning potential capital support with clinical advancement. Clinical Development The closing follows Telomir's recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-Zn for the treatment of advanced and metastatic … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model June 15, 2026 | 7 min read Twitter LinkedIn Facebook Email Print Insulin Resistance Was Normalized Follow … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Will Telomir Pharmaceuticals Bounce Back? News Platform Pricing Trading Guides Trading 101 Blog Level 2 Quotes Trading Terminology Stop Limit Orders Relative Volume Market Makers Guide Margin Rate Explainer Pivot Points beginner guides How to Day Trade for a Living What to Look for Before Investing Short Selling Day Trading Essentials How To Buy Stocks Stock Split Guide Psychology of Trading Technical Analysis Fundamental Analysis day trading Stocks to Watch AI Penny Stocks Day Trading Scanners Paper Trading Guide Low Float Stocks Pattern Trader Rule How to's How to Read Stock Charts Craft You … or as an endorsement, recommendation or sponsorship of any company, security or fund. StocksToTrade cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional … list. Frequency of text messages may vary; reply STOP to opt-out. Normal rates apply and consent is not a condition of purchase as you can always receive info by calling us directly. This website may record your interactions with it and future calls may be recorded/monitored. I agree, Submit
S-1 1 forms-1.htm As filed with the Securities and Exchange Commission on November 14, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TELOMIR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Florida 2834 87-2606031 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) … ffering price will be between $[●] and $[●] per share. We intend to apply to have shares of our common stock listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “TELO”. If shares of our common stock are not approved for listing on Nasdaq, we will not consummate this offering. No assurance can be given that our application will be approved. We are an “emerging growth company” as defined in the federal securitie … research, publicly available information, and industry publications. We did not fund and are not otherwise affiliated with any of the sources cited in this prospectus. The market research, publicly available information, and industry publications that we use generally state that the information contained therein has been obtained from sources believed to be reliable. The information therein represents the most recently available data from the relevant sources and publications … ng, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements; ● our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; ● our ability to advance product candidates into, and successfully complete, clinical trials; ` … s are ongoing or planned. Upon completion of the toxicology studies, we plan to submit to the FDA an Investigational New Drug application, IND for TELOMIR-1, focused on investigating TELOMIR-1 for the treatment of hemochromatosis. We may consider a second IND for post-chemotherapy recovery. All pre-clinical studies described in this section were
Telomir Pharmaceuticals Secures FDA IND Clearance for TNBC Therapy | Telomir Pharmaceuticals, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue … China’s National Medical Products Administration (NMPA) approved the marketing application for Anbenitamab Injection submitted by Shanghai Jinmante Biotechnology Co., Ltd. This approval marks an important advancement in the treatment landscape for HER2-positive gastric cancer and gastroesophageal junction adenocarcinoma. Anbenitamab, in combination with chemotherapy, is indicated for: ✔ Adult patients with locally advanced or metastatic HER2-positive gastric cancer ✔ Gastroe
WEBSITE TERMS & CONDITIONS | Overview Overview THE SCIENCE RESEARCH RESEARCH PIPELINE ABOUT US MANAGEMENT BOARD OF DIRECTORS ADVISORS NEWS & EVENTS INVESTORS CONTACT US Select Page TERMS & CONDITIONS Terms & Conditions Last updated: September 16, 2022 Notice to Our Readers Telomir Pharmaceuticals, Inc. (“Telomir”, “we”, “us” or “our”) provides the services available on its website at telomirpharma.com and any of our other websites, mobile applications or other online services that link to these terms and conditions (“Website”) to you subject to the following terms and cond … part, for any purpose without our prior written consent. 3. Limited License We grant you a limited, revocable, and non-exclusive license to access and make personal, non-commercial use of the Website, provided such use excludes use of any personal information which may be found on the Website. Please note that you may not frame or utilize framing techniques to enclose the Website or any portion thereof without our prior written consent. The limited license set forth in this … ary and non-confidential. By transmitting or posting any Submission, you hereby grant us a nonexclusive, royalty-free, fully paid up, perpetual, transferable, irrevocable, and fully sublicensable right to use, reproduce, modify, adapt, publish, sell, assign, translate, create derivative works from, distribute and display any Submission in any form, media or technology, whether now known or hereafter developed, alone or as part of other works. You also acknowledge that we may … all claims arising from your claims to any rights in any Submission. 6. Mobile Application Terms To the extent this agreement applies to your use of a Telomir mobile application, this Section 6 applies to your use of the mobile application, in addition to the rest of the Terms and Conditions. You acknowledge that you are entering into the Terms and Conditions with us and not with the operator of the mobile platform on which the app operates (“Platform”); that the Platform an … nd the Platform may enforce them; that we are solely responsible for the mobile application and its associated data; that the Platform makes no warranty with respect to the mobile application and its associated data and has no obligation whatsoever to furnish any maintenance and support services for the mobile application; that the Platform is no